Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...

Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

Compass Pathways' COMP005 trial met its primary endpoint in TRD, but modest results sparked a 47% drop in shares amid ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...

The COMP360 program aims to evaluate the safety and efficacy of COMP360 psilocybin, a synthetic, proprietary formulation of psilocybin under investigation for difficult-to-treat mental health ...

A single dose of a synthetic form of psilocybin is safe and clinically meaningful in reducing treatment-resistant depression, ...